Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Scopus)
2 Downloads (Pure)
Original languageEnglish
Pages (from-to)153-164
Number of pages12
JournalThe European Journal Of Health Economics
Volume21
DOIs
Publication statusPublished - 2019

Cite this